Previous 10 | Next 10 |
Clinical-stage biotech, Palisade Bio (NASDAQ:PALI) is trading ~84% higher in the pre-market Tuesday after the company announced that the U.S. regulators cleared a Phase 3 trial for its lead candidate LB1148. With the “Study May Proceed” letter from the U.S. Food and Dr...
CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced that the Company received a “Study May Proceed” letter fr...
Palisade Bio (NASDAQ:PALI) has filed for a $100M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for working capital and general corporate purposes. The offering can include common ...
Palisade Bio press release (NASDAQ:PALI): FY GAAP EPS of -$3.39 beats by $0.54. Cash and cash equivalents as of December 31, 2021, of $10.5M Shares -1.72% PM. For further details see: Palisade Bio GAAP EPS of -$3.39 beats by $0.54
CARLSBAD, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic gastrointestinal (GI) c...
Gainers: Zai Lab (NASDAQ:ZLAB) +27%. 111 (NASDAQ:YI) +26%. LianBio (NASDAQ:LIAN) +22%. BeiGene BGNE +20%. Palisade Bio PALI +10%. Losers: Talis Biomedical (NASDAQ:TLIS) -42%. Incannex Healthcare (NASDAQ:IXHL) -32%. NLS Pharmaceutics NLSP&...
Palisade Bio (PALI +12.3%) said data from pooled-analysis of studies suggested that LB1148 has the potential to prevent postoperative adhesions in patients undergoing bowel resection surgery. Data from the studies — LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-C...
Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 1...
Dallas, Texas--(Newsfile Corp. - March 14, 2022) - Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company's data bei...
CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence ...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...